News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–26
Matches
26
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

26 matching headlines

Ticker or company: INBXMain company stories
Clear
Latest

Stock Traders Daily Market update

Trading the Move, Not the Narrative: (INBX) Edition

This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.

Main company 🇺🇸 United States
Read at Stock Traders Daily
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Stock Titan Market update Main company 🇺🇸 United States

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Analyst action Main company 🇺🇸 United States

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages

Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com India Earnings Main company 🇺🇸 United States

Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data

Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold"

Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) from a "Sell" to a "Hold" rating, bringing the consensus rating for the stock to "Hold" with an average price target of $150. This upgrade comes despite the company reporting a quarterly loss of $2.15 per …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday

Inhibrx Biosciences (INBX) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $2.28 per share, following a previous quarter where the company missed expectations with a $2.15 per share loss. The stock, which …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

(INBX) Volatility Zones as Tactical Triggers

This article analyzes Inhibrx Biosciences Inc Com (NASDAQ: INBX), highlighting positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It identifies elevated downside risk and provides AI-generated institutional trading strategies for different risk profiles. The analysis includes position trading, momentum …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America

Bank of America Corporation has reported a beneficial ownership of 857,318 shares of Inhibrx Biosciences (INBX) common stock, which represents 5.9% of the class. This ownership is held through various affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Inhibrx Biosciences Inc (INBX) Institutional Confidence

The article analyzes the institutional confidence score for Inhibrx Biosciences Inc (INBX), which currently stands at 7.00, placing it 80th in its industry. Institutional shareholding has increased to 84.51%, with Andreas Halvorsen being the largest shareholder. The report also lists other significant institutional shareholders …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Balance sheet Main company 🇺🇸 United States

Inhibrx Biosciences (INBX) Expands Its Credit Facility, Is The Valuation Risk Priced In?

Inhibrx Biosciences (INBX) recently expanded its credit facility to $500 million, leading to a reassessment of its valuation by investors, despite a strong year-to-date return. The company's high price-to-book ratio of 55.6x, compared to an industry average of 2.4x, reflects its negative equity and …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga España Earnings Main company 🇺🇸 United States

Inhibrx Biosciences Market Sentiment

The article provides a market sentiment overview for Inhibrx Biosciences (INBX), detailing analyst consensus, short interest, and recent analyst actions. Key signals indicate a "Buy" consensus from analysts with a significant upside on the price target, alongside a high short interest percentage. The analyst …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800

This article provides a comprehensive stock analysis of Inhibrx Biosciences Inc (INBX), highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite a predicted medium-term downtrend, multiple analysts rate it as "Buy" with a high …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P.

SummitTX Capital L.P. significantly increased its stake in Inhibrx Biosciences (NASDAQ:INBX) by 66.3% during the first quarter, now owning 137,821 shares valued at approximately $9.3 million. Other institutional investors also adjusted their holdings, with institutional investors and hedge funds collectively owning 82.46% of the …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Inhibrx Biosciences Inc (INBX) Cash Flow

This article provides a comprehensive overview of Inhibrx Biosciences Inc's (INBX) cash flow statement, breaking down quarterly and annual data for operating, investing, and financing activities. It features detailed financial figures for various cash flow components, including net income, capital expenditures, and changes in …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX

Inhibrx Biosciences, Inc. (NASDAQ: INBX) generated $1.30 million USD in revenue last year, primarily from its Biologic Therapeutic segment. This represents a significant increase from the previous year's $200,000 USD. The United States was the company's largest contributor to revenue.

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Inhibrx Biosciences Inc (INBX), listing major shareholders and their respective proportions. It also presents institutional shareholding trends over several quarters and highlights shareholder activity, including changes in holdings for key investors. Additionally, the article includes a section …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Earnings Main company 🇺🇸 United States

Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?

Inhibrx Biosciences expanded its credit facility to $500.0 million with Oxford Finance, including an immediate $100.0 million Term C Loan. This move reduces short-term financing pressure and offers management more flexibility for trials, but also introduces higher leverage and financial risk. The company's investment …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Market update Main company 🇺🇸 United States

Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Balance sheet Main company 🇺🇸 United States

Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit

Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Balance sheet Main company 🇺🇸 United States

Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants

Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collateral. These …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Balance sheet Main company 🇺🇸 United States

Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its drug candidates. The agreement also adjusts …

INBX main company
Sharemaestro market context Price above Trend Line 52 weeks +253.5% INBX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context